Therapeutics Company Announces Clinical Trial Results For Glioblastoma Treatment

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, has recently announced findings from a Phase II/III clinical trial evaluating their novel drug, paxalisib, for the treatment of glioblastoma. Glioblastoma is a highly aggressive and life-threatening brain cancer, representing one of the greatest unmet needs in oncology today. The trial, known as GBM AGILE, is a global, adaptive trial sponsored by the Global Coalition for Adaptive Research (GCAR). $Kazia Therapeutics (KZIA.US)$